Deals And Sunshine At J.P. Morgan, But Biopharma Outlook Remains Mixed

Initial excitement over a few small deals announced at the opening of J.P. Morgan tapered off as approaching exclusivity losses, a lack of big takeouts and political uncertainty weighed on sentiment.